ACS Omega,
Journal Year:
2023,
Volume and Issue:
8(41), P. 38118 - 38129
Published: Oct. 3, 2023
Alzheimer's
disease
(AD)
is
a
neurodegenerative
disorder
that
impairs
neurocognitive
function.
Acetylcholinesterase
(AChE)
and
β-site
APP
cleaving
enzyme
1
(BACE1)
are
the
two
main
proteins
implicated
in
AD.
Indeed,
major
available
commercial
drugs
(donepezil,
rivastigmine,
galantamine)
against
AChE
inhibitors.
However,
none
of
these
known
to
reverse
or
reduce
pathophysiological
condition
since
there
multiple
contributing
factors
Therefore,
need
develop
multitarget-directed
ligand
approach
for
its
treatment.
In
present
study,
plant
bioactive
compounds
were
screened
their
BACE1
inhibition
potential
by
conducting
molecular
docking
studies.
Considering
score
pharmacokinetic
properties,
limonin,
peimisine,
serratanine
B,
withanolide
A
selected
as
lead
compounds.
Molecular
dynamics
simulations
protein-ligand
complexes
confirmed
conformational
energetically
stabilized
enzyme-inhibitor
complexes.
The
was
validated
vitro
assay.
Withanolide
inhibited
(IC50
value
107
μM)
showed
mixed-type
inhibition.
At
this
concentration,
it
activity
57.10%
stated
most
effective.
Both
compounds,
well
crude
extracts,
found
have
no
cytotoxic
effect
on
SH-SY5Y
cell
line.
Inorganics,
Journal Year:
2023,
Volume and Issue:
11(8), P. 321 - 321
Published: July 29, 2023
Herein
we
report
the
synthesis
of
organic
selenide-based
maleanilic
and
succinanilic
acids
in
good
yields
(up
to
95%).
Their
structural
identities
were
elucidated
by
spectroscopic
techniques
(e.g.,
IR,
1H-
&
13C-NMR,
MS).
The
ADMET
analysis,
molecule
electrostatic
potential
map,
DFT,
frontier
molecular
orbital
used
study
organoselenium
compounds’
pharmacokinetics,
drug-likeness
characteristics,
geometries,
chemical
electronic
properties.
Moreover,
a
docking
tool
was
employed
investigate
selenides’
ability
inhibit
SARS-CoV-2
Mpro
target
(PDB:
7BFB).
Within
this
context,
selenides
exhibited
promising
binding
affinities
receptor
following
order
(12
>
11
10
9
7
8).
Furthermore,
dynamics
simulations
also
carried
out
for
200
ns
evaluate
exact
behavior
most
active
compound
(12)
within
pocket
compared
with
its
co-crystallized
inhibitor
(Co).
Journal of Biomolecular Structure and Dynamics,
Journal Year:
2022,
Volume and Issue:
unknown, P. 1 - 18
Published: June 8, 2022
In
this
article,
we
describe
a
set
of
subsequent
five-steps
chemical
reactions
to
synthesize
ferrocene
derivative
named
1-(5-(diphenylphosphaneyl)cyclopenta-1,3-dien-1-yl)ethyl)imino)-1,3-dihydroisobenzofuran-5-yl)methanol
(compound
10).
Structural
characterization
10
and
its
intermediate
products
was
also
performed
reported
attest
their
formation.
A
molecular
docking
study
propose
the
novel
synthesized
(10)
as
potential
antitumor
candidate
targeting
mitogen-activated
protein
(MAP)
kinases
interacting
kinase
(Mnk)
1.
The
computed
score
at
-9.50
kcal/mol
compared
native
anticancer
staurosporine
-8.72
postulated
promising
activity.
Also,
dynamics
(MD)
simulations
were
carried
out
for
500
ns
followed
by
MM-GBSA-binding
free
energy
calculations
both
docked
complexes
give
more
deep
insights
into
dynamic
behavior
in
physiological
conditions.
Furthermore,
DFT
unravel
some
physiochemical
characteristics
(10).
quantum
mechanics
shed
light
on
structural
electrochemical
configurations
which
would
open
horizon
further
investigation.
HighlightsThe
synthesis
10)
described.Structural
characterizations
performed.DFT
calculations,
docking,
dynamics,
MM-GBSA
out.Computational
studies
revealed
through
inhibiting
1.Communicated
Ramaswamy
H.
Sarma.
Journal of Medicinal Chemistry,
Journal Year:
2022,
Volume and Issue:
66(1), P. 777 - 792
Published: Dec. 16, 2022
Telomerase
is
an
outstanding
biological
target
for
cancer
treatment.
BIBR1532
a
non-nucleoside
selective
telomerase
inhibitor;
however,
it
experiences
ineligible
pharmacokinetics.
Herein,
we
aimed
to
design
new
BIBR1532-based
analogues
as
promising
inhibitors.
Therefore,
two
novel
series
of
pyridazine-linked
cyclopenta[b]thiophene
(8a-f)
and
tetrahydro-1-benzothiophene
(9a-f)
were
synthesized.
A
quantitative
real-time
polymerase
chain
reaction
was
utilized
investigate
the
inhibitory
activity
candidates.
Notably,
8e
9e
exhibited
best
inhibition
profiles.
Moreover,
showed
strong
antitumor
effects
against
both
MCF-7
A549
cell
lines.
The
on
cycle
apoptosis
measured.
Besides,
evaluated
its
in
vivo
using
solid
Ehrlich
carcinoma.
reduction
tumor
weight
volume
greater
than
doxorubicin.
Also,
molecular
docking
ADME
studies
performed.
Finally,
SAR
study
conducted
gain
further
insights
into
different
potentials
upon
variable
structural
modifications.
International Journal of Molecular Sciences,
Journal Year:
2022,
Volume and Issue:
23(20), P. 12235 - 12235
Published: Oct. 13, 2022
In
this
article,
34
anticoagulant
drugs
were
screened
in
silico
against
the
main
protease
(Mpro)
of
SARS-CoV-2
using
molecular
docking
tools.
Idraparinux,
fondaparinux,
eptifibatide,
heparin,
and
ticagrelor
demonstrated
highest
binding
affinities
towards
Mpro.
A
dynamics
study
at
200
ns
was
also
carried
out
for
most
promising
anticoagulants
to
provide
insights
into
dynamic
thermodynamic
properties
compounds.
Moreover,
a
quantum
mechanical
conducted
which
helped
us
attest
some
findings.
biological
evaluation
(in
vitro)
compounds
performed
by
carrying
MTT
cytotoxicity
assay
crystal
violet
order
assess
inhibitory
concentration
50
(IC50).
It
is
worth
noting
that
displayed
intrinsic
potential
inhibition
with
an
IC50
value
5.60
µM
safety
index
25.33.
addition,
fondaparinux
sodium
dabigatran
showed
activities
values
8.60
9.40
µM,
respectively,
indexes
17.60
15.10,
respectively.
Mpro
enzyme
investigated
utilizing
tipranavir
as
reference
standard.
Interestingly,
attained
2.36
surpassing
(IC50
=
7.38
µM)
more
than
three-fold.
Furthermore,
highly
eligible
10.59
µM.
Finally,
SAR
discussed,
counting
on
findings
both
vitro
approaches.
Journal of Enzyme Inhibition and Medicinal Chemistry,
Journal Year:
2022,
Volume and Issue:
37(1), P. 2112 - 2132
Published: July 31, 2022
The
global
outbreak
of
the
COVID-19
pandemic
provokes
scientists
to
make
a
prompt
development
new
effective
therapeutic
interventions
for
battle
against
SARS-CoV-2.
A
series